Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulse BiosciencesPLSE +4.63%31 Debt-to-Equity is 0.11 as of Mar. 2026, which is 48% below its 10-year median of 0.21. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Pulse Biosciences ranks better than 66.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Pulse Biosciences's Debt-to-Equity or its related term are showing as below:
PLSE'
s Debt-to-Equity Range Over the Past 10 Years
Min: -33.79 Med: 0.21 Max: 12.17
Current: 0.11
During the past 12 years, the highest Debt-to-Equity Ratio of Pulse Biosciences was 12.17. The lowest was -33.79. And the median was 0.21.
PLSE's Debt-to-Equity is ranked better than 66.1% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs PLSE: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Pulse Biosciences Debt-to-Equity Related Terms
Pulse Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLSE vs LMAT, XRAY, KMTS: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a Debt-to-Equity of 0.11 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pulse Biosciences and its competitors. This is 48% below median its historical median of 0.21. According to the industry distribution chart, Pulse Biosciences ranks #239 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Pulse Biosciences' Debt-to-Equity too high?
Pulse Biosciences' current Debt-to-Equity of 0.11 is 48% below median its 10-year median of 0.21. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Pulse Biosciences' value of 0.11 is 52.2% below this industry median. Based on the distribution chart, Pulse Biosciences ranks #239 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Debt-to-Equity compare to LMAT and XRAY?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #239 out of 705 companies for Debt-to-Equity. This puts Pulse Biosciences in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Pulse Biosciences' value of 0.11 is 52.2% below this benchmark. While the company's 10-year median is 0.21 vs. the industry median of 0.23, Pulse Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current Debt-to-Equity of 0.11 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current Debt-to-Equity is 0.11, which is 48% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Debt-to-Equity of 0.11. The current Debt-to-Equity is 0.11, which is 48% below median its 10-year median of 0.21 and 52.2% below the Medical Devices & Instruments industry median of 0.23. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Debt-to-Equity is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
